Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of rituximab on the course of acute humoral rejection after kidney transplantation
2007-003213-13Phase 3Active
- Sponsor
- CHRU Tours
- Start
- Sep 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of rituximab in kidney allograft rejection (2 arms), sponsored by CHRU Tours. Primary endpoint: Composite treatment failure at day 12. Started Sep 2007; status: active.
02
Drugs
rituximab
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2007-003213-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003213-13.